Since CDDP‐based chemotherapy is the standard first line in SCLC,5, 6, 7 HER2‐targeting NIR‐PIT could be a choice following the failure of the CDDP regimen for HER2‐positive SCLC (Figure 5). Here, ERBB2 is linked to small cell lung carcinoma.